Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Zydelig (idelalisib) - Important Safety Information from Gilead Sciences Ltd. as approved by the HPRA
Notice type:
3rd Party Publications
Date:
24/03/2016
Problem Or Issue:
Important Safety Information communication from Gilead Sciences Ltd. on restrictions on the use of Zydelig (idelalisib) for the treatment of chronic lymphocytic leukaemia (CLL) and relapsed follicular lymphoma (FL) following new clinical trial results.
Important Safety Information - Zydelig (idelalisib)
« Back
Date Printed: 29/03/2024